|
|
|
|
|
by harleyk
3165 days ago
|
|
Really happy for Solugen's success and what this means for other biotechs seeking to augment traditional petromethods with enzymatic ones. Can you help us better understand how you use CRISPR/Cas9 to mutate the protein? Your enzyme is proprietary, sounds like human protein, but mutated in certain positions prob to increase rate, but how do you use Cas9? I assume like other biotechs you purify this single protein using either E. coli or yeast with protein on plasmid. So why use Cas9 instead of site-directed mutagenesis? |
|